| Tremfya (guselkumab) / J&J |
2017-003249-18: TIGERS study proposes to take mini fragments of synovial tissue to study the molecular patterns present in psoriatic arthritis, in order to to identify markers of disease progression and response to treatment with Ustekinumab, Guselkumab or Adalimumab to analyze and compare different expression patterns within synovial and cutaneous tissue , and to investigate whether molecular diagnosis allows to predict the evolution of the disease in the long term, as well as the therapeutic response. |
|
|
| Not yet recruiting | 2 | 36 | Europe | Ustekinumab, adalimumab, L04AC05, Powder and solvent for solution for injection, Solution for infusion, Solution for injection in pre-filled syringe, Tremfya 100 mg solution for injection in pre-filled syringe., STELARA® 45 mg/0.5 mL or 90 mg/mL solution in a single-dose prefilled syringe, Humira 40 mg solution for injection in pre-filled syringe | Cliniques Universitaires Saint-Luc, Janssen Pharmaceutica | Psoriatic arthritis (PsA), Psoriatic arthritis (PsA) is a type of chronic inflammatory arthritis, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-001048-70: Comparison of secukinumab versus guselkumab in clearing psoriatic plaques refractory to ustekinumab |
|
|
| Not yet recruiting | 2 | 40 | Europe | Secukinumab, Tremfya, AIN457, Solution for injection in pre-filled syringe, Solution for injection, Cosentyx, Tremfya | Novartis Pharma AG, Novartis Pharma AG | Plaque Psoriasis, Psoriasis looks like red, raised scaly areas of the skin, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2020-000622-26: A Proof-of-Concept Study of Guselkumab in the Treatment of Subjects with New-Onset or Relapsing Giant Cell Arteritis |
|
|
| Not yet recruiting | 2 | 60 | Europe | Guselkumab, CNTO1959, Solution for infusion, Solution for injection | Janssen-Cilag International N.V., JANSSEN CILAG INTERNATIONAL NV, Janssen Pharmaceutica N.V., Janssen Research R&D | Giant Cell Arteritis, Giant Cell Arteritis, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-004451-20: A multicenter, open label, single-arm pilot study to evaluate the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP) Multizentrische, offene, einarmige Pilotstudie zur Bewertung der Wirksamkeit und Sicherheit von Guselkumab bei Patienten mit mittelschwerer bis schwerer, palmoplantarer Pustulose (PPP) |
|
|
| Not yet recruiting | 2 | 50 | Europe | Guselkumab, CNTO 1959, Solution for injection in pre-filled syringe | Rheinische Friedrich-Wilhelms-Universität Bonn, Janssen-Cilag GmbH | Adult men and women with palmoplantar pustulosis Erwachsene männliche und weibliche Probanden mit palmoplantarer Pustulose, Adult men and women with palmoplantar pustulosis Erwachsene männliche und weibliche Probanden mit palmoplantarer Pustulose, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-000271-36: Immunotherapy with the bioactive substance Guselkumab in patients suffering from oral skin disease Lichen-Planus using an open-label, parallel, multi-center phase IIa trial design |
|
|
| Not yet recruiting | 2 | 45 | Europe | Guselkumab, Solution for infusion in pre-filled syringe, Tremfya | Philipps University Marburg, Janssen-Cilag GmbH | severe oral lichen planus (LP) with variable phenotype (erosive, ulcerating, hyperplastic/leucoplastic, and combined forms), severe oral skin disease lichen planus (LP) with variable outer appearance, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-002012-31: A Study of the Efficacy and Safety of Guselkumab and Golimumab in Participants with Active Psoriatic Arthritis Estudio para evaluar la eficacia y la seguridad de Guselkumab y Golimumab en pacientes con artritis psoriásica activa |
|
|
| Ongoing | 2 | 90 | Europe | guselkumab, golimumab, CNTO1959, CNTO148, Solution for injection in pre-filled syringe | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development | Active Psoriatic Arthritis Artritis Psoriásica Activa, Psoriatic Arthritis Artritis Psoriásica, Diseases [C] - Immune System Diseases [C20] | | | | |
2018-001510-15: A Proof-of-concept Study of the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis |
|
|
| Not yet recruiting | 2 | 210 | Europe | Guselkumab, Golimumab, CNTO1959, CNTO148, Solution for infusion in pre-filled syringe, Solution for injection in pre-filled syringe, TREMFYA®, Simponi® | Janssen-Cilag International NV, Janssen Research & Development, LLC | Ulcerative Colitis, Inflammation of Digestive Tract, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT03975153: Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP) |
|
|
| Completed | 2 | 15 | US | guselkumab, Tremfya | Oregon Health and Science University | Pityriasis Rubra Pilaris | 08/22 | 03/24 | | |
2018-003155-38: A Study of the Efficacy and Safety of Guselkumab in Participants with Active Lupus Nephritis |
|
|
| Not yet recruiting | 2 | 60 | Europe | Guselkumab, CNTO1959, Solution for injection in pre-filled syringe, TREMFYA | Janssen-Cilag International NV, Janssen Research & Development | Active Lupus Nephritis, Active Lupus Nephritis, Diseases [C] - Immune System Diseases [C20] | | | | |
| Terminated | 2 | 33 | Europe, US, RoW | Guselkumab Dose 1, CNTO 1959, Placebo, Guselkumab Dose 2, CNTO1959, Standard-of-care treatment | Janssen Research & Development, LLC | Lupus Nephritis | 02/23 | 02/23 | | |
NCT04683029: A Study of Guselkumab in Participants With Systemic Sclerosis |
|
|
| Active, not recruiting | 2 | 56 | Japan | Guselkumab Dose 1, Guselkumab Dose 2, Placebo | Janssen Pharmaceutical K.K. | Scleroderma, Systemic | 05/23 | 07/24 | | |
THEIA, NCT04633447: A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis |
|
|
| Terminated | 2 | 53 | Europe, Canada, US, RoW | Guselkumab, Tremfya, CNTO 1959, Placebo | Janssen Research & Development, LLC | Giant Cell Arteritis | 05/24 | 05/24 | | |
| Active, not recruiting | 2 | 91 | Europe, US, RoW | Guselkumab, TREMFYA, CNTO1959, Golimumab, SIMPONI, CNTO148, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Arthritis, Psoriatic | 05/24 | 08/24 | | |
| Recruiting | 2 | 715 | Europe, Canada, Japan, US, RoW | Guselkumab, Golimumab, JNJ-78934804, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Crohn's Disease | 05/25 | 03/29 | | |
| Recruiting | 2 | 550 | Europe, Canada, Japan, US, RoW | Guselkumab, Golimumab, JNJ-78934804, Placebo | Janssen Research & Development, LLC, Janssen Research & Development | Colitis, Ulcerative | 05/25 | 03/29 | | |
